tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MedPlus Subsidiary Faces Drug License Suspension in Telangana

Story Highlights
MedPlus Subsidiary Faces Drug License Suspension in Telangana

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

MedPlus Health Services Ltd. ( (IN:MEDPLUS) ) has issued an announcement.

MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for a Drug License at its Telangana stores. The suspensions, issued by the Drugs Control Administration, Medchal, are due to violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The suspensions are expected to result in a potential revenue loss of approximately Rs 0.48 lacs and Rs 1.28 lacs for the affected stores. This development may impact the company’s financial operations and highlights regulatory compliance challenges within the industry.

More about MedPlus Health Services Ltd.

MedPlus Health Services Ltd. operates in the healthcare industry, primarily focusing on providing pharmaceutical products and health-related services. The company is known for its extensive network of retail pharmacy outlets across India, catering to a wide range of healthcare needs.

Average Trading Volume: 21,259

Technical Sentiment Signal: Sell

Current Market Cap: 91.48B INR

For a thorough assessment of MEDPLUS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1